Praxis Precision Medicines, Inc. $PRAX Shares Bought by Vanguard Group Inc.

Key Points

• Vanguard Group increased its stake in Praxis Precision Medicines by 15.3% in Q4, buying 193,647 shares to hold 1,460,933 shares (about 5.80% of the company) valued at roughly $430.6 million.
• Analyst consensus is a "Buy" with a $590.78 average price target; analyst coverage includes 5 Strong Buy, 12 Buy, 1 Hold and 2 Sell ratings, reflecting mixed but overall favorable sentiment.
• Praxis shares opened around $333.30 (market cap ~$9.29B) and have a 52‑week range of $34.89–$356.00, while the company reported a wider-than-expected quarterly loss of $3.50 per share and remains a clinical‑stage biopharma focused on CNS disorders.

Vanguard Group Inc. lifted its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 15.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,460,933 shares of the company's stock after buying an additional 193,647 shares during the period. Vanguard Group Inc. owned approximately 5.80% of Praxis Precision Medicines worth $430,595,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. NBC Securities Inc. purchased a new position in shares of Praxis Precision Medicines during the 4th quarter worth $38,000. GAMMA Investing LLC grew its holdings in shares of Praxis Precision Medicines by 58.7% in the fourth quarter. GAMMA Investing LLC now owns 238 shares of the company's stock valued at $70,000 after purchasing an additional 88 shares during the period. Tower Research Capital LLC TRC increased its position in Praxis Precision Medicines by 24.3% during the second quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company's stock worth $77,000 after purchasing an additional 359 shares during the last quarter. AlphaQuest LLC raised its stake in Praxis Precision Medicines by 1,623.3% during the third quarter. AlphaQuest LLC now owns 1,999 shares of the company's stock worth $106,000 after purchasing an additional 1,883 shares during the period. Finally, Farther Finance Advisors LLC raised its stake in Praxis Precision Medicines by 60.0% during the fourth quarter. Farther Finance Advisors LLC now owns 368 shares of the company's stock worth $108,000 after purchasing an additional 138 shares during the period. Hedge funds and other institutional investors own 67.84% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Wells Fargo & Company set a $305.00 price objective on Praxis Precision Medicines and gave the company an "equal weight" rating in a report on Friday, February 20th. Robert W. Baird set a $433.00 target price on Praxis Precision Medicines and gave the company an "outperform" rating in a research report on Friday, February 20th. Truist Financial raised Praxis Precision Medicines to a "strong-buy" rating in a research note on Wednesday, March 25th. TD Cowen reiterated a "buy" rating on shares of Praxis Precision Medicines in a report on Thursday, January 29th. Finally, Wedbush raised their price objective on Praxis Precision Medicines from $95.00 to $130.00 and gave the stock an "underperform" rating in a research report on Friday, February 20th. Five research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $590.78.

Praxis Precision Medicines Stock Performance

Praxis Precision Medicines stock opened at $333.30 on Wednesday. The company has a market capitalization of $9.29 billion, a PE ratio of -24.76 and a beta of 2.76. Praxis Precision Medicines, Inc. has a fifty-two week low of $34.89 and a fifty-two week high of $356.00. The firm has a 50 day moving average price of $318.06 and a 200 day moving average price of $275.31.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its quarterly earnings results on Thursday, February 19th. The company reported ($3.50) EPS for the quarter, missing analysts' consensus estimates of ($3.00) by ($0.50). As a group, equities research analysts forecast that Praxis Precision Medicines, Inc. will post -14.88 earnings per share for the current year.

Praxis Precision Medicines Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company's pipeline includes several lead candidates at various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.